Literature DB >> 28647522

Functional Medium-Term Results After Autologous Matrix-Induced Chondrogenesis for Osteochondral Lesions of the Talus: A 5-Year Prospective Cohort Study.

Oliver Gottschalk1, Sebastian Altenberger2, Sebastian Baumbach3, Stefanie Kriegelstein2, Florian Dreyer2, Alexander Mehlhorn2, Hubert Hörterer2, Andreas Töpfer2, Anke Röser2, Markus Walther4.   

Abstract

Autologous matrix-induced chondrogenesis (AMIC) has gained popularity in the treatment of osteochondral lesions of the talus. Previous studies have presented promising short-term results for AMIC talar osteochondral lesion repair, a 1-step technique using a collagen type I/III bilayer matrix. The aim of the present study was to investigate the mid-term effects. The 5-year results of a prospective cohort study are presented. All patients underwent an open AMIC procedure for a talar osteochondral lesion. Data analysis included general demographic data, preoperative magnetic resonance imaging findings, intraoperative details, and German version of the Foot Function Index (FFI-D) scores preoperatively and at 1 and 5 years after surgery. The primary outcome variable was the longitudinal effect of the procedure, and the influence of various variables on the outcome was tested. Of 47 consecutive patients, 21 (45%) were included. Of the 21 patients, 8 were female (38%) and 13 were male (62%), with a mean age of 37 ± 15 (range 15 to 62) years and a body mass index of 26 ± 5 (range 20 to 38) kg/m2. The defect size was 1.4 ± 0.9 (range 0.2 to 4.0) cm2. The FFI-D decreased significantly from preoperatively to 1 year postoperatively (56 ± 18 versus 33 ± 25; p = .003), with a further, nonsignificant decrease between the 1- and 5-year follow-up examination (33 ± 25 versus 24 ± 21; p = .457). Similar results were found for the FFI-D subscales of function and pain. The body mass index and lesion size showed a positive correlation with the preoperative FFI-D overall and subscale scores. These results showed a significant improvement in pain and function after the AMIC procedure, with a significant return to sports by the 5-year follow-up point. The greatest improvement overall was seen within the first year; however, further clinical satisfaction among the patients was noticeable after 5 years.
Copyright © 2017 American College of Foot and Ankle Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  AMIC; microfracturing; osteochondral defects; osteochondrosis dissecans osteochondral lesion; sports; talus

Mesh:

Year:  2017        PMID: 28647522     DOI: 10.1053/j.jfas.2017.05.002

Source DB:  PubMed          Journal:  J Foot Ankle Surg        ISSN: 1067-2516            Impact factor:   1.286


  13 in total

1.  Arthroscopic microfracture vs. arthroscopic autologous matrix-induced chondrogenesis for the treatment of articular cartilage defects of the talus.

Authors:  Christoph Becher; Michael Alexander Malahias; Moataz Mahmoud Ali; Nicola Maffulli; Hajo Thermann
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2018-11-03       Impact factor: 4.342

2.  Large variation in management of talar osteochondral lesions among foot and ankle surgeons: results from an international survey.

Authors:  Matteo Guelfi; Christopher W DiGiovanni; James Calder; Francesc Malagelada; Guillaume Cordier; Masato Takao; Jorge Batista; Caio Nery; Marino Delmi; Miki Dalmau-Pastor; Giovanni Carcuro; Gabriel Khazen; Jordi Vega
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2020-11-22       Impact factor: 4.342

3.  Influence of the Medial Malleolus Osteotomy on the Clinical Outcome of M-BMS + I/III Collagen Scaffold in Medial Talar Osteochondral Lesion (German Cartilage Register/Knorpelregister DGOU).

Authors:  Oliver Gottschalk; Sebastian Felix Baumbach; Sebastian Altenberger; Daniel Körner; Matthias Aurich; Christian Plaass; Sarah Ettinger; Daniel Guenther; Christoph Becher; Hubert Hörterer; Markus Walther
Journal:  Cartilage       Date:  2020-10-08       Impact factor: 3.117

4.  High-Density Autologous Chondrocyte Implantation as Treatment for Ankle Osteochondral Defects.

Authors:  Juan Manuel López-Alcorocho; Isabel Guillén-Vicente; Elena Rodríguez-Iñigo; Ramón Navarro; Rosa Caballero-Santos; Marta Guillén-Vicente; Mercedes Casqueiro; Tomás F Fernández-Jaén; Fernando Sanz; Santiago Arauz; Steve Abelow; Pedro Guillén-García
Journal:  Cartilage       Date:  2019-03-17       Impact factor: 4.634

5.  Autologous matrix-induced chondrogenesis for the treatment of osteochondral lesions of the talus: A systematic review.

Authors:  Michael-Alexander Malahias; Lazaros Kostretzis; Panayiotis D Megaloikonomos; Erwin-Brian Cantiller; Dimitrios Chytas; Hajo Thermann; Christoph Becher
Journal:  Orthop Rev (Pavia)       Date:  2021-01-29

6.  AMIC for Focal Osteochondral Defect of the Talar Shoulder.

Authors:  Christian Götze; Christian Nieder; Hanna Felder; Filippo Migliorini
Journal:  Life (Basel)       Date:  2020-12-05

7.  [Research progress in surgical procedures for osteochondral lesions of talus].

Authors:  Xinbo Wu; Haichao Zhou; Yunfeng Yang
Journal:  Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi       Date:  2019-10-15

8.  Adhesive Hydrogels for Maxillofacial Tissue Regeneration Using Minimally Invasive Procedures.

Authors:  Christoph Salzlechner; Tabasom Haghighi; Isabella Huebscher; Anders Runge Walther; Sophie Schell; Alexander Gardner; Gerhard Undt; Ricardo M P da Silva; Cécile A Dreiss; Kathleen Fan; Eileen Gentleman
Journal:  Adv Healthc Mater       Date:  2020-01-14       Impact factor: 11.092

Review 9.  Return to Sports After Surgical Treatment of Osteochondral Defects of the Talus: A Systematic Review of 2347 Cases.

Authors:  Jason A H Steman; Jari Dahmen; Kaj T A Lambers; Gino M M J Kerkhoffs
Journal:  Orthop J Sports Med       Date:  2019-10-22

10.  AMIC for traumatic focal osteochondral defect of the talar shoulder: a 5 years follow-up prospective cohort study.

Authors:  Christian Götze; Christian Nieder; Hanna Felder; Christian Dominik Peterlein; Filippo Migliorini
Journal:  BMC Musculoskelet Disord       Date:  2021-07-24       Impact factor: 2.362

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.